published meta-analysis   sensitivity analysis   studies

anti-interleukin-6 in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsRashad, 2021 2.86 [1.36; 6.01] Rashad, 2021 0.35 [0.17; 0.74] 1.00[0.13; 7.83]Rashad, 2021, Rashad, 2021293%298seriousnot evaluable deathsdetailed resultsRashad, 2021 2.16 [1.14; 4.09] Rashad, 2021 0.46 [0.24; 0.88] 1.00[0.22; 4.55]Rashad, 2021, Rashad, 2021291%298seriousnot evaluable deaths (time to event analysis only)detailed resultsRashad, 2021 2.16 [1.14; 4.09] Rashad, 2021 0.46 [0.24; 0.88] 1.00[0.22; 4.55]Rashad, 2021, Rashad, 2021291%298seriousnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-03 02:15 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 557,635,1236,553,628,646,645,607,395 - roots T: 290